GT Biopharma (GTBP) had the best year between 2008 and 2014 by a US stock in 2012, returning 3,044,698,370%.

ASSET	YEAR	% RETURN
GT Biopharma (GTBP)	2012	3,044,698,370%
PCB Bancorp (PCB)	2014	527,363,000%
Castellum (CTM)	2011	6,521,639.13%
Future Fintech (FTFT)	2008	6,410,156.41%
Sequans Communications (SQNS)	2011	3,349,297.59%
QXO (QXO)	2012	1,151,950%
Inventrust Properties (IVT)	2014	1,067,615%
Nutex Health (NUTX)	2013	749,900.2%
Sandstorm Gold Ltd N (SAND)	2010	432,700%
Ferguson (FERG)	2010	227,815.73%
NextTrip (NTRP)	2010	199,900%
Aris Mining (ARMN)	2010	184,239.52%
PetVivo (PETV)	2014	64,689.33%
BioLineRx (BLRX)	2011	30,621.52%
PharmaCyte Biotech (PMCB)	2008	27,947.62%
Titan Pharmaceuticals (TTNP)	2009	8,150%
Intellinetics (INLX)	2012	8,066.67%
Weatherford International (WFRD)	2008	7,300%
Metalla Royalty & Streaming (MTA)	2009	6,281.93%
BTCS (BTCS)	2010	5,920.01%
Oxley Bridge Acquisition Limited Class A Ordinary Shares (OBA)	2008	5,749.06%
IT Tech Packaging (ITP)	2009	3,642.86%
Nixxy (NIXX)	2008	3,400%
Aura Minerals Inc Common Shares (AUGO)	2009	3,008.37%
Nova Lifestyle I (NVFY)	2011	2,733.33%